JPMorgan maintained its Overweight rating on Mankind Pharma Ltd (MANKIND:IN) and increased the price target from INR3,000.00 ...

Mankind's revenue from operations rose to Rs 3,230 crore in Q3FY25, a 24 per cent Y-o-Y rise from Rs 2,607 crore reported in ...

Mankind Pharma Ltd.'s share price declined more than 5% during early trade on Friday after the company's third-quarter ...

Mankind Pharma's Q3 net profit was impacted by the $1.6 billion acquisition of Bharat Serums and Vaccines (BSV), which came ...

Mankind Pharma's net profit fell 16.5% to Rs 384 crore in Q3 FY25, while revenue rose 24% to Rs 3,230 crore. The company's domestic business grew 15.5% YoY and exports surged to Rs 457 crore.

Jefferies maintains a Buy rating on JB Pharma citing strong CDMO growth potential and a 34% upside. Know more about it.

India's Mankind Pharma reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses.

As long as the market defends the midline of Bollinger Bands, the trend may remain in favour of bulls despite Monday's profit ...

Mankind Pharma Limited (Mankind), established in 1995, is a fast-growing pharmaceuticals and consumer healthcare company. It ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Mankind Pharma Ltd share price previously? Mankind Pharma Ltd share price was down by -2.11% from the previous ...

Mankind Pharma's shares dropped almost 6 per cent on 24 January, impacted by a decline in the company's net profit for ...